For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Medifast Inc’s stock clocked out at $11.28, up 1.17% from its previous closing price of $11.15. In other words, the price has increased by $1.17 from its previous closing price. On the day, 0.11 million shares were traded. MED stock price reached its highest trading level at $11.32 during the session, while it also had its lowest trading level at $11.13.
Ratios:
To gain a deeper understanding of MED’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.71 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 190.74. For the most recent quarter (mrq), Quick Ratio is recorded 3.95 and its Current Ratio is at 4.45. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In the most recent recommendation for the company, DA Davidson on November 05, 2024, Upgraded its rating to Neutral and sets its target price to $17 from $16.50 previously.
On June 05, 2024, DA Davidson Downgraded its rating to Underperform which previously was Neutral and also lowered its target price recommendation from $25 to $17.50.
On October 13, 2023, Stephens started tracking the stock assigning a Equal-Weight rating and target price of $82.Stephens initiated its Equal-Weight rating on October 13, 2023, with a $82 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 13 ’25 when Chard Daniel R bought 381 shares for $13.13 per share. The transaction valued at 5,003 led to the insider holds 149,698 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MED now has a Market Capitalization of 123981560 and an Enterprise Value of -45323360. As of this moment, Medifast’s Price-to-Earnings (P/E) ratio for their current fiscal year is 539.71. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.29 while its Price-to-Book (P/B) ratio in mrq is 0.58. Its current Enterprise Value per Revenue stands at -0.105 whereas that against EBITDA is -2.183.
Stock Price History:
The Beta on a monthly basis for MED is 0.50, which has changed by -0.3721847 over the last 52 weeks, in comparison to a change of 0.14446163 over the same period for the S&P500. Over the past 52 weeks, MED has reached a high of $18.59, while it has fallen to a 52-week low of $10.36. The 50-Day Moving Average of the stock is -3.77%, while the 200-Day Moving Average is calculated to be -14.17%.
Shares Statistics:
It appears that MED traded 205.09K shares on average per day over the past three months and 366880 shares per day over the past ten days. A total of 10.99M shares are outstanding, with a floating share count of 10.63M. Insiders hold about 3.31% of the company’s shares, while institutions hold 84.43% stake in the company. Shares short for MED as of 1764288000 were 1854480 with a Short Ratio of 9.72, compared to 1761868800 on 2040495. Therefore, it implies a Short% of Shares Outstanding of 1854480 and a Short% of Float of 17.34.
Earnings Estimates
The performance of Medifast Inc (MED) in the stock market is under the watchful eye of 1.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.36 and low estimates of -$0.36.
Analysts are recommending an EPS of between -$0.12 and -$0.12 for the fiscal current year, implying an average EPS of -$0.12. EPS for the following year is -$1.61, with 1.0 analysts recommending between -$1.61 and -$1.61.
Revenue Estimates
In. The current quarter, 1 analysts expect revenue to total $71.4M. It ranges from a high estimate of $71.4M to a low estimate of $71.4M. As of. The current estimate, Medifast Inc’s year-ago sales were $119MFor the next quarter, 1 analysts are estimating revenue of $85.5M. There is a high estimate of $85.5M for the next quarter, whereas the lowest estimate is $85.5M.
A total of 1 analysts have provided revenue estimates for MED’s current fiscal year. The highest revenue estimate was $382.1M, while the lowest revenue estimate was $382.1M, resulting in an average revenue estimate of $382.1M. In the same quarter a year ago, actual revenue was $602.46MBased on 1 analysts’ estimates, the company’s revenue will be $337.5M in the next fiscal year. The high estimate is $337.5M and the low estimate is $337.5M.
